RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 13 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 13

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  2. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  3. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  4. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  5. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  6. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  7. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  8. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  9. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  10. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  11. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  12. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  13. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07059650, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.

    Inclusion criterion 2

  3. ECOG status score of 0 to 2.

    Inclusion criterion 13

  4. Presence of at least one radiologically measurable lesion in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.

    Inclusion criterion 14

  5. The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.

    Exclusion criterion 11

  6. Women who are pregnant or breastfeeding.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07059650, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Cohort 1:
  • Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.
  • Disease stage II to IV by Ann Arbor Classification.
  • Life expectancy ≥ 12 months.
  • Cohort 2, 3:
  • Pathologically confirmed DLBCL patients who have received adequate first-line treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen).
  • Relapsed or refractory to first-line R-CHOP-like regimen.
  • For patients who have received only one line of therapy, if the patient has not received autologous stem cell transplantation, the investigator needs to assess as unsuitable or the patient refuses intensive chemotherapy and hematopoietic stem cell transplantation.
  • Life expectancy ≥ 6 months.
  • Patients must also meet all of the following criteria to be included in this study:
  • All patients must provide a signed and dated written informed consent prior to any study-specific procedure, sampling, and analysis.
  • Patients must be ≥ 18 years of age at the time of informed consent.
  • ECOG status score of 0 to 2.
  • Presence of at least one radiologically measurable lesion in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.
  • Adequate bone marrow hematopoietic reserve and organ function.
  • No uncontrolled medical complications.
  • Patients should be able to follow the relevant requirements of this study for medication and follow-up.
  • Willing to comply with contraceptive restrictions.

Exclusion Criteria:

  • Cohort 2, 3:

a. Hematopoietic stem cell transplantation, cell therapy, or gene therapy within 90 days prior to first dose. Radiation therapy within 14 days prior to first dose. Chemotherapy and small-molecule targeted therapy were not terminated within 5 half-lives before the first dose; macromolecule drug therapy (such as antibody therapy) was not terminated within 28 days before the first dose.

  • All patients should not be included in this study if they have any of the following conditions:
  • Indolent lymphoma-transformed DLBCL, primary mediastinal lymphoma, lymphoma involving the central nervous system, or DLBCL with MYC and BCL2 rearrangements.
  • Prior use of BTK inhibitors.
  • Vaccination with live attenuated vaccines or viral vector vaccines within 4 weeks prior to enrollment.
  • Currently taking vitamin K antagonists, taking 2 or more antiplatelet/anticoagulant drugs at the same time, drugs/herbs or supplements known to potently induce or inhibit CYP3A enzyme activity, proton pump inhibitor drugs, anti-tumor traditional Chinese medicine or failing to meet the protocol-specified withdrawal time before administration in this study.
  • Major surgery within 4 weeks or anticipated surgery after the start of this study. Or insufficiently recovered from any toxicity and/or complications of previous intervention.
  • Clinically significant cardiac disorders. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.
  • Active infectious diseases.
  • Intractable nausea and vomiting that cannot be well controlled by supportive treatment, chronic gastrointestinal diseases, dysphagia, or previous surgical resection of the intestinal segment may affect the adequate absorption of the drug.
  • The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.
  • Patients with hypersensitivity to DZD8586 drug excipients or other chemical analogues.
  • Patients with severe or uncontrolled systemic diseases, including poorly controlled hypertension and active bleeding constitution.
  • Serious medical or psychiatric illness that could affect participation in the study or could compromise the ability to consent
  • Women who are pregnant or breastfeeding.

Quoted from ClinicalTrials.gov, NCT07059650, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07059650, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07059650